EUVIMEDEUVIMED entdecken
Open Access

Streptococcus agalactiae glycolipids promote virulence by thwarting immune cell clearance

Luke R Joyce iD, Sol Kim iD, Brady L Spencer iD, Priya M Christensen iD, Kelli L Palmer iD, Ziqiang Guan iD, Julie A Siegenthaler iD, Kelly S Doran iD

Science Advances · 31.05.2024 · 10 (22)

DOI: 10.1126/sciadv.adn7848 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 31.05.2024. Verfasst von Luke R Joyce und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA. Hauptthemen laut MEDLINE: Streptococcus agalactiae, Glycolipids, Streptococcal Infections. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Streptococcus agalactiae [group B Streptococcus (GBS)] is a leading cause of neonatal meningitis, with late-onset disease (LOD) occurring after gastrointestinal tract colonization in infants. Bacterial membrane lipids are essential for host-pathogen interactions, and the functions of glycolipids are yet to be fully elucidated. GBS synthesizes three major glycolipids: glucosyl-diacylglycerol (Glc-DAG), diglucosyl-DAG (Glc 2 -DAG), and lysyl-Glc-DAG (Lys-Glc-DAG). Here, we identify the enzyme, IagB, as responsible for biosynthesis of Glc-DAG, the precursor for the two other glycolipids in GBS. To examine the collective role of glycolipids to GBS virulence, we adapted a murine model of neonatal meningitis to simulate LOD. The GBS∆ iagB mutant traversed the gut-epithelial barrier comparable to wild type but was severely attenuated in bloodstream survival, resulting in decreased bacterial loads in the brain. The GBS∆ iagB mutant was more susceptible to neutrophil killing and membrane targeting by host antimicrobial peptides. This work reveals an unexplored function of GBS glycolipids with their ability to protect the bacterial cell from host antimicrobial killing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Streptococcus agalactiaeGlycolipidsStreptococcal InfectionsAnimalsMiceVirulenceHumansDisease Models, AnimalHost-Pathogen InteractionsNeutrophilsMutation

Substanzen

Glycolipids

Autor:innen und Institutionen

  • Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
  • Department of Pediatrics, Section of Developmental Biology, University of Colorado School of Medicine, Aurora, CO, USA.
  • Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX, USA.
  • Department of Biochemistry, Duke University Medical Center, Durham, NC, USA.

ORCID-Profile: Luke R Joyce, Sol Kim, Brady L Spencer, Priya M Christensen, Kelli L Palmer, Ziqiang Guan, Julie A Siegenthaler, Kelly S Doran

Förderung

  • NIAID NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Joyce, L. R., Kim, S., Spencer, B. L., Christensen, P. M., Palmer, K. L., Guan, Z., Siegenthaler, J. A., & Doran, K. S. (2024). Streptococcus agalactiae glycolipids promote virulence by thwarting immune cell clearance. Science Advances, 10(22). https://doi.org/10.1126/sciadv.adn7848

Vancouver

Joyce LR, Kim S, Spencer BL, Christensen PM, Palmer KL, Guan Z, et al. Streptococcus agalactiae glycolipids promote virulence by thwarting immune cell clearance. Science Advances. 2024;10(22). doi:10.1126/sciadv.adn7848

BibTeX
@article{Joyce2024,
  author = {Joyce, Luke R and Kim, Sol and Spencer, Brady L and Christensen, Priya M and Palmer, Kelli L and Guan, Ziqiang and Siegenthaler, Julie A and Doran, Kelly S},
  title = {Streptococcus agalactiae glycolipids promote virulence by thwarting immune cell clearance},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {22},
  doi = {10.1126/sciadv.adn7848}
}
Kostenlos starten →